4. Hrvatski kongres o reprodukcijskom zdravlju, planiranju obitelji,

kontracepciji i IVF-u


s međunarodnim sudjelovanjem

Prijevremena insuficijencija jajnika (dijagnoza, terapija, socijalno zamrzavanje) / Premature ovarian failure (diagnosis, therapy, social freezing)

Miro Šimun Alebić










Ovarian reserve



Wallace and Kelsey. Human Ovarian Reserve from Conception to the Menopause. PLoS ONE 2011; 5: e8772 the pool of resting follicles at any given age

Low or diminished ovarian reserve

- mostly age-associated but also caused by conditions affecting the ovaries
- iregular menses
- poor response to controlled ovarian stimulation
- diminished reproductive potential
- incidence: 9 to 24% (Keay, et al., 1997).




Management of women with premature ovarian insufficiency

Guideline of the European Society of Human Reproduction and Embryology

POI Guideline Development Gr

Ovarian insufficiency

loss of ovarian activity



Terminology

Primary Ovarian Insufficiency
Premature Ovarian Failure

Gonadal dysgenesis

Premature menopause

Early menopause

Hypergonadotropic hypogonadism

Premature Ovarian Insufficiency

Ovarian dysgenesis

Primary ovarian failure

Hypergonadotropic amenorrhea

Climacterium praecox

Menopause praecox

- "premature ovarian insufficiency" should be used to describe this condition in research and clinical practice.
- loss of ovarian activity before age 40



Low or diminished ovarian reserve




Ovarian insufficiency



Ovarian reserve tests:

- •AMH
- •AFC




Log 10 PF

R = -0.80p < 0.0001

Table 2. Average Age at Menopause for Individual Women Aged 20 to 49 Years, When Different Serum Concentrations of AMH Are Assumed

AMH,		Age, y														
ng/dL	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50
0.1	33 (27-36)	34 (28-38)	35 (29-39)	36 (30-40)	37 (31-41)	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)
0.3	34 (28-38)	35 (29-39)	36 (30-40)	37 (31-41)	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)
0.5	35 (29-39)	36 (30-40)	37 (31-41)	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)
0.7	36 (30-40)	37 (31-41)	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)
0.9	37 (31-41)	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50-67)
1.1	39 (32-43)	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50-67)	63 (51-69)
1.3	40 (33-44)	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)
1.5	41 (34-46)	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)
1.7	43 (35-47)	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)	
1.9	44 (36-49)	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)		
2.1	45 (37-50)	47 (38-52)	48 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)			
2.3	47 (38-52)	49 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)				
2.5	49 (40-54)	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)					
2.7	50 (41-55)	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)						
2.9	52 (42-57)	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)							
3.1	53 (44-59)	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)								
3.3	55 (45-61)	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)									
3.5	57 (47-63)	59 (48-65)	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)										
3.7	59 (48-65)	61 (50->65)	63 (53->65)	65 (53->65)	>65 (55->65)											
3.9	61 (50->65)	63 (51->65)	65 (53->65)	>65 (55->65)												
4.1	63 (51->65)	65 (53->65)	>65 (55->65)													
4.3	65 (53->65)	>65 (55->65)														
4.5	>65 (55->65)															

Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerianhormone. J Clin Endocrinol Metab 2013;98:729-735.



Broer SL, Eijkema ns MJ, Scheffer GJ, et al. Antimulleria n hormon е predicts menopa use: a longterm followup study in normoo vulatory women. J Clin Endocri nol Metab 011;96: 2532-2539.


- AMH and mother's age of natural menopause
 - currently the most promising predictors of age at menopause
- models
 - lack the capacity to predict extreme
 - provide wide prediction intervals


AMH is currently not applicable for predicting menopause or the end of natural fertility in the day-to-day clinical practice

Introduction

 age at menopause, the end of natural fertility and the start of subfertility
 a fixed temporal relationship

> te Velde and Pearson, 2002 Broekmans et al., 2009





12.8 frozen oocytes should be Sertilized to acchieve Phe delivery !!

ART results with frozen oocytes: data from the Italian ART registry (2005-2013). J Assist Reprod Genet. 2016 Jan;33(1):123-8

Oocyte freezing

delay for a cancer treatment negative effect on estrogen-sensitive tumors from high estradiol levels during stimulation

Embryo freezing

reproductive autonomy is limited - partner's or donor sperm required ethical, legal and religious implications regarding disposal of embryos in case patient dies

Ovarian tissue cryopreservation (OTC)

does not delay the start of cancer therapy and avoids the risk of ovarian stimulation.

no need for partner or donor sperm

preserves a larger pool of follicles and allows for the resumption of ovarian function.

only technique available for preserving fertility in prepubertal girls.

POI - diagnosis




- menstrual disturbance and biochemical confirmation
- diagnostic criteria:
 - -oligo/amenorrhea for at least 4 months, and
 - —an elevated FSH level > 25 IU/l on two occasions > 4 weeks apart
 - —in women <40 years</p>
- suspect if:
 - estrogen-deficiency symptoms
 - amenorrhea/oligomenorrhea
 - below the age of 40 years

FERTILITY

- a small chance of spontaneous pregnancy
- no interventions that have been reliably shown to increase ovarian activity and natural conception rates
- use contraception to avoid pregnancy
- oocyte donation established option for fertility

- if established - missed opportunity for fartility preservation



BONE HEALTH - ↓BMD ↑fracture risk

CARDIOVASCULAR HEALTH - ↑ CVD risks


SEXUAL AND GENITO-URINARY FUNCTION

NEUROLOGICAL HEALTH





- avoidance of smoking
- maintenance of normal body weight
- HRT



Hormone replacement therapy (HRT)

- treatment of low estrogen symptoms
- potential role in :
 - primary prevention of CVD
 - bone protection

not been found to increase the risk of breast cancer before the age of natural menopause

Hormone replacement therapy (HRT)

- progestogen in combination if uterus is intact
- 17β-estradiol rather than ethinylestradiol or conjugated equine
- oral cyclical combined treatment the strongest evidence of endometrial protection
- consider patient preference for route and method of administration
- clinical review annually, attention to compliance
- no routine monitoring tests are required

POI – causes and interventions

- iatrogenic
 - discuss POI as a potential consequence prior a medical or surgical intervention
- non-iatrogenic
 - chromosomal analysis
 - screening for 21OH-Ab and thyroid (TPO-Ab) antibodies
- unexplained or idiopathic
 - significant number



Primary Ovarian Insufficiency

Premature Ovarian Failure

Gonadal dysgenesis

Premature menopause

Early menopause

Hypergonadotropic hypogonadism

Premature Ovarian Insufficiency

Ovarian dysgenesis

Primary ovarian failure

Hypergonadotropic amenorrhea

Climacterium praecox

Menopause praecox

PRIJEVREMENA INSUFICIJENCIJA JAJNIKA

oligo/amenorrhea ≥ 4 months 2x FSH > 25 IU/l > 4 weeks apart in women <40 years

- healthy lifestyle
 - weight-bearing exercise
 - avoidance of smoking
 - maintenance of normal body weight



HRT

TO TAKE HOME

i-hong Ho^c,) Hosoi^f,

of

1 of



*Department of Obstetrics and Gynecology, Program of Reproductive and Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305-5317; bpeartment of Obstetrics and Gynecology, Akita University School of Medicine, Akita 010-8543, Japan; and State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China

mature eggs